Literature DB >> 20974570

SEOM clinical guidelines for the treatment of diffuse large B-cell lymphoma.

José Gómez Codina1, Pilar Sabín Domínguez, Mariano Provencio Pulla, Antonio Rueda Domínguez, Dolores Isla Casado.   

Abstract

Diffuse large B-cell non-Hodgkin's lymphoma (LDCGB) is one of the best examples of chemotherapy curable malignant diseases. This "Oncoguía SEOM" summarizes the basic directions of staging and recommended treatment options. The staging study should be thorough and includes clinical, laboratory, diagnostic imaging and nuclear medicine. Treatment depends on patient characteristics and comorbidity and on disease extension and prognostic factors. In localized cases, chemoimmunotherapy (CHOP-R) of short duration, followed by involved-field irradiation is the preferred option. In advanced stages, the association of CHOP-like chemotherapy and Rituximab has been a major breakthrough in terms of cure rate. It is important do not forget the supportive treatment in these patients.

Entities:  

Mesh:

Year:  2010        PMID: 20974570     DOI: 10.1007/s12094-010-0593-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  19 in total

1.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Authors:  Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

Review 2.  [GESIDA/PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients].

Authors:  Pilar Miralles; Juan Berenguer; José María Ribera Santasusana; Felipe Calvo; Joaquín Díaz Mediavilla; José Luis Díez-Martín; José Gomez Codina; José López Aldeguer; Rafael Rubio; Jesús Santos; Eulalia Valencia
Journal:  Med Clin (Barc)       Date:  2008-03-08       Impact factor: 1.725

3.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

4.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

Authors:  T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

Review 5.  Lymphoma and myeloma in older patients.

Authors:  Eric H Westin; Dan L Longo
Journal:  Semin Oncol       Date:  2004-04       Impact factor: 4.929

6.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

8.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

Authors:  Herve Tilly; Eric Lepage; Bertrand Coiffier; Michel Blanc; Raoul Herbrecht; Andre Bosly; Michel Attal; Georges Fillet; Catherine Guettier; Thierry Jo Molina; Christian Gisselbrecht; Felix Reyes
Journal:  Blood       Date:  2003-08-14       Impact factor: 22.113

9.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

Authors:  Sandra J Horning; Edie Weller; KyungMann Kim; John D Earle; Michael J O'Connell; Thomas M Habermann; John H Glick
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544

10.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Bernd Metzner; Dirk Hasenclever; Norbert Schmitz; Bertram Glass; Christian Rübe; Markus Loeffler
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  1 in total

1.  The relevance of the Spanish Society for Medical Oncology (SEOM)'s clinical oncology guidelines.

Authors:  Dolores Isla Casado; Antonio González-Martín; Emilio Alba Conejo
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.